A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention
Status:
Terminated
Trial end date:
2020-07-29
Target enrollment:
Participant gender:
Summary
Crohn's Disease (CD) is a chronic pathology characterized by exacerbations and remissions.
Recurrent inflammation can cause bowel strictures, fistulae (often perianal) or abscesses. CD
often requires intestinal resection. Surgery in CD is not curative, Therefore, endoscopic
follow-up 6-12 months after surgery is recommended. Given the association between enteric
bacteria and postoperative CD recurrence, antibacterial agents were shown to be effective in
reducing the severity of endoscopic recurrence, but prolonged administration causes
significant toxicity. The efficacy of "systemic antibiotics" and the experimental evidence of
the central role of luminal flora as an essential factor in the development of post chirurgic
CD recurrence provide the rationale for evaluating a locally acting antibiotic like
Rifaximin.